AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12730476 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein supplementation
Number of subjects: 0
Study 12730476 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0
Study 12730476 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 0
Study 12730476 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplements
Number of subjects: 0
Study 11039737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyzer measurements (single image) in healthy volunteers
Number of subjects: 55
Study 11039737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyzer measurements (single image) in patients with glaucoma
Number of subjects: 55
Study 11039737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyzer measurements (mean-of-three image)
Number of subjects: 55
Study 11039737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyzer measurements across three different instruments
Number of subjects: 55
Study 8659419 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT (HC) acquisition after contrast injection at 6 ml/sec
Number of subjects: 100
Study 8659419 — intervention group
Group type: COMPARATOR
Intervention: Dynamic sequential CT (DS) acquisition after contrast injection at 2 ml/sec
Number of subjects: 100
Study 8659419 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT (HC)
Number of subjects: 100
Study 8659419 — intervention group
Group type: COMPARATOR
Intervention: Dynamic sequential CT (DS)
Number of subjects: 100
Study 1573555 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin complexed on xanthan, administered in a unique daily dose
Number of subjects: 100
Study 1573555 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin or furazolidone, administered for 5-10 days or longer
Number of subjects: 100
Study 3887877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (160 mg once daily, increased to 320 mg, 480 mg, and 640 mg if necessary)
Number of subjects: 33
Study 3887877 — intervention group
Group type: COMPARATOR
Intervention: Procainamide (1 gm three times/day, increased to 1.5 gm three times/day if plasma concentrations were insufficient)
Number of subjects: 33
Study 3887877 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sotalol and procainamide
Number of subjects: 33
Study 3887877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 33
Study 3887877 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 33
Study 30917287 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry consumption (MC)
Number of subjects: 12
Study 30917287 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prior to HF meal with Montmorency tart cherry consumption (E+MC)
Number of subjects: 12
Study 30917287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 30917287 — intervention group
Group type: COMPARATOR
Intervention: Exercise prior to HF meal with placebo (E+P)
Number of subjects: 12
Study 28791808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography guided injection of hyaluronic acid
Number of subjects: 61
Study 28791808 — intervention group
Group type: COMPARATOR
Intervention: Blind injection of hyaluronic acid
Number of subjects: 61
Study 28791808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sonography guided and Blind injection)
Number of subjects: 61
Study 27566502 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on use of sleep-enhancing tools (eye mask, ear plugs, white noise machine)
Number of subjects: 120
Study 27566502 — intervention group
Group type: COMPARATOR
Intervention: General benefits of sleep discussion (control)
Number of subjects: 120
Study 24182765 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact(®) perioperatively (group C)
Number of subjects: 312
Study 24182765 — intervention group
Group type: COMPARATOR
Intervention: Reference diet (group A, control)
Number of subjects: 312
Study 23569894 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of Vernonia amygdalina
Number of subjects: 0
Study 23569894 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunace(®)
Number of subjects: 0
Study 23569894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Vernonia amygdalina extract and Immunace(®)
Number of subjects: 0
Study 23569894 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20685190 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office training for pediatric primary care clinicians
Number of subjects: 397
Study 20685190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 397
Study 20685190 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with possible or probable SDQ scores
Number of subjects: 397
Study 18242357 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 1109
Study 18242357 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg intravenously and/or 500 mg orally twice daily for 10 days
Number of subjects: 1109
Study 15848357 — intervention group
Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 1622
Study 15848357 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic repair
Number of subjects: 1622
Study 15848357 — intervention group
Group type: EXPERIMENTAL
Intervention: Open and laparoscopic repair
Number of subjects: 1622
Study 12629102 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 18
Study 12629102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10482826 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 197
Study 10482826 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 197
Study 7851594 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 in seminal plasma
Number of subjects: 46
Study 7851594 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-19.9 in seminal plasma
Number of subjects: 46
Study 7851594 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-195 in seminal plasma
Number of subjects: 46
Study 2117186 — intervention group
Group type: EXPERIMENTAL
Intervention: OM‐85 BV
Number of subjects: 265
Study 2117186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 7006476 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of isoniazid, rifampin, and ethambutol for 8 weeks, followed by daily for 18 weeks
Number of subjects: 411
Study 7006476 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly administration of isoniazid, rifampin, and ethambutol during the continuation phase
Number of subjects: 411
Study 7006476 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly administration of isoniazid, rifampin, and ethambutol during the continuation phase
Number of subjects: 411
Study 7006476 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly administration of isoniazid and rifampin during the continuation phase
Number of subjects: 411
Study 31853709 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen (Tegsedi™)
Number of subjects: 0
Study 31853709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31337958 — intervention group
Group type: EXPERIMENTAL
Intervention: NXT15906F6-250 mg
Number of subjects: 90
Study 31337958 — intervention group
Group type: EXPERIMENTAL
Intervention: NXT15906F6-400 mg
Number of subjects: 90
Study 31337958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27718143 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day (12h sampling)
Number of subjects: 16
Study 27718143 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day (24h sampling)
Number of subjects: 16
Study 25982703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone triage consultation
Number of subjects: 9154
Study 25982703 — intervention group
Group type: COMPARATOR
Intervention: GP face-to-face consultation
Number of subjects: 9154
Study 25982703 — intervention group
Group type: COMPARATOR
Intervention: GP telephone triage consultation with no subsequent same day care
Number of subjects: 9154
Study 25982703 — intervention group
Group type: COMPARATOR
Intervention: GP telephone triage consultation with subsequent face-to-face consultation
Number of subjects: 9154
Study 25982703 — intervention group
Group type: COMPARATOR
Intervention: Nurse telephone triage consultation with subsequent face-to-face consultation
Number of subjects: 9154
Study 22849311 — intervention group
Group type: EXPERIMENTAL
Intervention: Green leafy porridges (including coconut milk and various leaf extracts)
Number of subjects: 0
Study 22849311 — intervention group
Group type: COMPARATOR
Intervention: Glucose control
Number of subjects: 0
Study 20805142 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured resin-modified glass ionomer cement (RMGIC) with 15% phosphoric acid etching and without water contamination
Number of subjects: 100
Study 20805142 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured resin-modified glass ionomer cement (RMGIC) with 15% phosphoric acid etching and with water contamination
Number of subjects: 100
Study 20805142 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured resin-modified glass ionomer cement (RMGIC) without acid etching and without water contamination
Number of subjects: 100
Study 20805142 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured resin-modified glass ionomer cement (RMGIC) without acid etching and with water contamination
Number of subjects: 100
Study 20805142 — intervention group
Group type: COMPARATOR
Intervention: Conventional light-cured Transbond composite resin under acid etching and without water contamination
Number of subjects: 100
Study 19632710 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with enhanced messages
Number of subjects: 601
Study 19632710 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast with enhanced messages
Number of subjects: 601
Study 19632710 — intervention group
Group type: COMPARATOR
Intervention: Neutral placebo
Number of subjects: 601
Study 19632710 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 601
Study 19632710 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast with neutral messages
Number of subjects: 601
Study 19632710 — intervention group
Group type: COMPARATOR
Intervention: Placebo with neutral messages
Number of subjects: 601
Study 17078894 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic interactive referral pro forma
Number of subjects: 265707
Study 17078894 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visit by a local colorectal surgeon
Number of subjects: 265707
Study 17078894 — intervention group
Group type: COMPARATOR
Intervention: Combined software arms (electronic pro forma and educational outreach)
Number of subjects: 265707
Study 17078894 — intervention group
Group type: COMPARATOR
Intervention: Combined educational outreach arms
Number of subjects: 265707
Study 17078894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro forma practices
Number of subjects: 265707
Study 15284371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg
Number of subjects: 10
Study 15284371 — intervention group
Group type: COMPARATOR
Intervention: Lutein supplement
Number of subjects: 10
Study 15284371 — intervention group
Group type: COMPARATOR
Intervention: Lutein ester supplement
Number of subjects: 10
Study 15284371 — intervention group
Group type: COMPARATOR
Intervention: Spinach
Number of subjects: 10
Study 10965395 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine oral syrup (50 mg, 10 mL)
Number of subjects: 36
Study 10965395 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine rectal suppository (50 mg)
Number of subjects: 36
Study 10965395 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine rectal suppository (two 12.5 mg)
Number of subjects: 36
Study 10965395 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine rectal suppository (25 mg)
Number of subjects: 36
Study 10965395 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations (oral syrup and rectal suppositories)
Number of subjects: 36
Study 10965395 — intervention group
Group type: EXPERIMENTAL
Intervention: Three suppository treatments
Number of subjects: 36
Study 9043723 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' estimates of cardiac output (CO)
Number of subjects: 35
Study 9043723 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetists' estimates of cardiac output (CO)
Number of subjects: 35
Study 9043723 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' estimates of systemic vascular resistance (SVR)
Number of subjects: 35
Study 9043723 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetists' estimates of systemic vascular resistance (SVR)
Number of subjects: 35
Study 9043723 — intervention group
Group type: EXPERIMENTAL
Intervention: Management based on subjective values
Number of subjects: 35
Study 7701651 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt endoscopy (group 1)
Number of subjects: 414
Study 7701651 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment strategy (group 2)
Number of subjects: 414
Study 2649339 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 5)
Number of subjects: 10
Study 2649339 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 5)
Number of subjects: 10
Study 367239 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxuridine (IDU)
Number of subjects: 10
Study 367239 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine (ara‐A)
Number of subjects: 10
Study 31820361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide plus indomethacin, enalapril, and spironolactone
Number of subjects: 22
Study 31820361 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin, enalapril, and spironolactone (Control)
Number of subjects: 22
Study 31182140 — intervention group
Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi (HGMX)
Number of subjects: 130
Study 31182140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 28562541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine-epinephrine
Number of subjects: 148
Study 28562541 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 148
Study 28562541 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine-epinephrine and Normal saline (Control)
Number of subjects: 148
Study 25486391 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Skills Training Program (ASTP)
Number of subjects: 61
Study 25486391 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Screening and Intervention for College Students (BASICS)
Number of subjects: 61
Study 25486391 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual Alcohol Diversion Program (ADP)
Number of subjects: 61
Study 24419119 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus PCV chemotherapy
Number of subjects: 251
Study 24419119 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 251
Study 24419119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study arms (RT and RT plus PCV)
Number of subjects: 251
Study 22209215 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention
Number of subjects: 250
Study 22209215 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 250
Study 19540386 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions (group 1 and group 3)
Number of subjects: 0
Study 19540386 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual interventions (group 2 and group 4)
Number of subjects: 0
Study 19540386 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group 5)
Number of subjects: 0
Study 18246682 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus intensive pulse light irradiation
Number of subjects: 96
Study 18246682 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 96
Study 15034745 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized ANN model
Number of subjects: 89
Study 15034745 — intervention group
Group type: EXPERIMENTAL
Intervention: Best kinetic model
Number of subjects: 89
Study 15034745 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximized model
Number of subjects: 89
Study 15034745 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologic model
Number of subjects: 89
Study 15034745 — intervention group
Group type: COMPARATOR
Intervention: Expert radiologist
Number of subjects: 89
Study 11588440 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB)
Number of subjects: 20
Study 11588440 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 20
Study 9050948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose GH: 16 IU/m2/week
Number of subjects: 67
Study 9050948 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GH: 28 IU/m2/week
Number of subjects: 67
Study 9050948 — intervention group
Group type: EXPERIMENTAL
Intervention: GH: 24 IU/m2/week + Oxa: 0.06 mg/kg/day
Number of subjects: 67
Study 9050948 — intervention group
Group type: COMPARATOR
Intervention: Untreated girls with TS
Number of subjects: 67
Study 8466063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscularly every 6 h after an initial dose of 60 mg
Number of subjects: 40
Study 8466063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 40
Study 8466063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3532404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (rengasil) combined with small doses of corticosteroids
Number of subjects: 93
Study 29923323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (intervention group)
Number of subjects: 14771
Study 29923323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14771
Study 26945321 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher density treatment
Number of subjects: 7
Study 26945321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower density treatment
Number of subjects: 7
Study 26945321 — intervention group
Group type: COMPARATOR
Intervention: Both treatment densities
Number of subjects: 7
Study 25231953 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) 10 mg/day plus Exemestane (EXE) 25 mg/day
Number of subjects: 410
Study 25231953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) plus Exemestane (EXE) 25 mg/day
Number of subjects: 410
Study 22405699 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 250
Study 22405699 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus long-term androgen deprivation (LTAD)
Number of subjects: 250
Study 21164551 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine collagen peptides (MCPs) 13 g daily for 3 months
Number of subjects: 100
Study 17645254 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture
Number of subjects: 80
Study 17645254 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular and body acupuncture
Number of subjects: 80
Study 17645254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined auricular and body acupuncture treatment plus moving cupping on back‐shu points
Number of subjects: 80
Study 16222322 — intervention group
Group type: COMPARATOR
Intervention: 5FU alone
Number of subjects: 1327
Study 16222322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU+LEV
Number of subjects: 1327
Study 16222322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU+FA
Number of subjects: 1327
Study 16222322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU+LEV+FA
Number of subjects: 1327
Study 11887541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide group (n = 26)
Number of subjects: 56
Study 11887541 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 30)
Number of subjects: 56
Study 11887541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 10208997 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab with low-dose heparin (70 U/kg initial bolus)
Number of subjects: 2792
Study 10208997 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab with standard-dose heparin (100 U/kg initial bolus)
Number of subjects: 2792
Study 10208997 — intervention group
Group type: COMPARATOR
Intervention: placebo with standard-dose heparin (100 U/kg initial bolus)
Number of subjects: 2792
Study 10208997 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab therapy
Number of subjects: 2792
Study 10208997 — intervention group
Group type: EXPERIMENTAL
Intervention: periprocedural myocardial infarctions suppressed by abciximab
Number of subjects: 2792
Study 7790694 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein diet (HP) at 1.5 g/kg body weight/day
Number of subjects: 24
Study 7790694 — intervention group
Group type: COMPARATOR
Intervention: Marginal Protein diet (MP) at 1.0 g/kg body weight/day
Number of subjects: 24
Study 2183599 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more cups of filter-brewed coffee per day
Number of subjects: 21
Study 2183599 — intervention group
Group type: COMPARATOR
Intervention: Control (no coffee consumption)
Number of subjects: 21
Study 7241554 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly structured sequence on colorectal cancer (n = 180)
Number of subjects: 245
Study 7241554 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured sequence on colorectal cancer (n = 180)
Number of subjects: 245
Study 7241554 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer self-instructional sequence (n = 65)
Number of subjects: 245
Study 31142441 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA) 10 mg
Number of subjects: 7020
Study 31142441 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA) 25 mg
Number of subjects: 7020
Study 31142441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 28196207 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg once daily (400 mg/d)
Number of subjects: 695